Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2023-12-23 Director's Dealing
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2023-12-23 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans. The text references multiple equity incentive plans and amendments to them, details about shares authorized for issuance, and legal and procedural information related to the registration. It is not a financial report, earnings release, or management discussion, but a regulatory filing specifically for securities registration under the Securities Act of 1933. Therefore, it fits the category of Regulatory Filings (RNS). The document length and content confirm it is the filing itself, not just an announcement.
2023-12-22 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes a preliminary prospectus for the resale of common stock by selling stockholders, details about the offering, risk factors, management discussion and analysis, and other disclosures typical of a registration statement. This is not an annual report, earnings release, or any other financial report but a capital markets filing related to financing and securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full registration statement, not just an announcement or a brief notice.
2023-12-22 English
SC 13G
Major Shareholding Notification
2023-12-13 English
4
Director's Dealing
2023-12-11 English
SC 13D/A
Major Shareholding Notification
2023-12-11 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.